Silicon Phthalocyanine (Pc 4) Photodynamic Therapy is a Safe Modality for Cutaneous Neoplasms: Results of a Phase 1 Clinical Trial

Overview

Journal Lasers Surg Med

Specialties General Surgery
Pharmacology

Date 2011 Jan 20

PMID 21246576

Citations 43

Authors

Elma D Baron

Christi L Malbasa

Diana Santo-Domingo

Pingfu Fu

Janine D Miller

Kaija K Hanneman

Andrew H Hsia

Nancy L Oleinick

Valdir C Colussi

Kevin D Cooper

Affiliations

Soon will be listed here.

Abstract

Background: Photodynamic therapy (PDT) is a non-invasive treatment for non-melanoma skin cancer. However, PDT systems currently used clinically have limitations such as pain and superficial tissue penetration. The silicon phthalocyanine Pc 4 is a second-generation photosensitizer with peak absorption in the far red at 675 nm.

Objective: To assess the safety and tolerability of topically applied Pc 4 followed by red light (Pc 4-PDT) in treating cutaneous neoplasms.

Study Design/materials And Methods: Forty three adults with a diagnosis of neoplasms including actinic keratoses, Bowen's disease, squamous cell carcinoma, basal cell carcinoma, or mycosis fungoides were treated with a single administration of Pc 4-PDT and followed for 14 days. The study utilized a light and Pc 4 dose escalation design in sequential groups of three subjects each.

Results: Pc 4-PDT was well tolerated with no significant local toxicity or increased photosensitivity. It has promising biologic effects, particularly in mycosis fungoides where 14 of 35 subjects demonstrated a clinical response, which correlates with Pc 4-PDT-induced apoptosis, as measured by increased active caspase-3 in the treated skin lesions.

Conclusions: Pc 4-PDT is a safe and tolerable treatment modality that effectively triggers apoptosis in cutaneous neoplasms such as mycosis fungoides.

Citing Articles

Photodynamic Therapy: Past, Current, and Future.

Aebisher D, Czech S, Dynarowicz K, Misiolek M, Komosinska-Vassev K, Kawczyk-Krupka A Int J Mol Sci. 2024; 25(20).

PMID: 39457108 PMC: 11508366. DOI: 10.3390/ijms252011325.

Photodynamic therapy for cancer: mechanisms, photosensitizers, nanocarriers, and clinical studies.

Zhao W, Wang L, Zhang M, Liu Z, Wu C, Pan X MedComm (2020). 2024; 5(7):e603.

PMID: 38911063 PMC: 11193138. DOI: 10.1002/mco2.603.

Theranostics with photodynamic therapy for personalized medicine: to see and to treat.

Wang Y, Staudinger J, Mindt T, Gasser G Theranostics. 2023; 13(15):5501-5544.

PMID: 37908729 PMC: 10614685. DOI: 10.7150/thno.87363.

Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization - a Thomas Dougherty Award for Excellence in PDT paper.

De Silva P, Saad M, Thomsen H, Bano S, Ashraf S, Hasan T J Porphyr Phthalocyanines. 2023; 24(11n12):1320-1360.

PMID: 37425217 PMC: 10327884. DOI: 10.1142/s1088424620300098.

An Update on Recent Advances of Photodynamic Therapy for Primary Cutaneous Lymphomas.

Liu W, Wang H, Yeh Y, Wong T Pharmaceutics. 2023; 15(5).

PMID: 37242570 PMC: 10223676. DOI: 10.3390/pharmaceutics15051328.

References

Ferguson J, Brown M, Alert D, Bielfeldt S, Brown J, Chardon A . Collaborative development of a sun protection factor test method: a proposed European Standard. COLIPA Task Force 'Sun Protection Measurement', Europe. Int J Cosmet Sci. 2009; 18(5):203-18. DOI: 10.1111/j.1467-2494.1996.tb00151.x. View

Morton C, Campbell S, Gupta G, Keohane S, Lear J, Zaki I . Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol. 2006; 155(5):1029-36. DOI: 10.1111/j.1365-2133.2006.07470.x. View

Paech V, Lorenzen T, Stoehr A, Lange K, Merz H, Meigel W . Remission of a cutaneous Mycosis fungoides after topical 5-ALA sensitisation and photodynamic therapy in a patient with advanced HIV-infection. Eur J Med Res. 2003; 7(11):477-9. View

Vonderheid E, Tan E, KANTOR A, Shrager L, Micaily B, VAN SCOTT E . Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989; 20(3):416-28. DOI: 10.1016/s0190-9622(89)70051-7. View

ZACKHEIM H, Epstein Jr E, Crain W . Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol. 1990; 22(5 Pt 1):802-10. DOI: 10.1016/0190-9622(90)70112-u. View

Braathen L, Szeimies R, Basset-Seguin N, Bissonnette R, Foley P, Pariser D . Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2006; 56(1):125-43. DOI: 10.1016/j.jaad.2006.06.006. View

Querfeld C, Rosen S, Kuzel T, Kirby K, Roenigk Jr H, Prinz B . Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005; 141(3):305-11. DOI: 10.1001/archderm.141.3.305. View

Xue L, Chiu S, Oleinick N . Photodynamic therapy-induced death of MCF-7 human breast cancer cells: a role for caspase-3 in the late steps of apoptosis but not for the critical lethal event. Exp Cell Res. 2001; 263(1):145-55. DOI: 10.1006/excr.2000.5108. View

Weinstock M, Gardstein B . Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999; 89(8):1240-4. PMC: 1508695. DOI: 10.2105/ajph.89.8.1240. View

10.

Grapengiesser S, Ericson M, Gudmundsson F, Larko O, Rosen A, Wennberg A . Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol. 2002; 27(6):493-7. DOI: 10.1046/j.1365-2230.2002.01065.x. View

11.

Ketabchi A, Macrobert A, Speight P, Bennett J . Induction of apoptotic cell death by photodynamic therapy in human keratinocytes. Arch Oral Biol. 1998; 43(2):143-9. DOI: 10.1016/s0003-9969(97)00079-4. View

12.

Steinbauer J, Schreml S, Babilas P, Zeman F, Karrer S, Landthaler M . Topical photodynamic therapy with porphyrin precursors--assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci. 2009; 8(8):1111-6. DOI: 10.1039/b823378k. View

13.

Zhao B, Yin J, Bilski P, Chignell C, Roberts J, He Y . Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol Appl Pharmacol. 2009; 241(2):163-72. PMC: 2783992. DOI: 10.1016/j.taap.2009.08.010. View

14.

Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens V . Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002; 138(3):325-32. DOI: 10.1001/archderm.138.3.325. View

15.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

16.

Orenstein A, Haik J, TAMIR J, Winkler E, Trau H, Malik Z . Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg. 2000; 26(8):765-9; discussion 769-70. DOI: 10.1046/j.1524-4725.2000.00056.x. View

17.

Edstrom D, Porwit A, Ros A . Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol. 2001; 81(3):184-8. DOI: 10.1080/000155501750376276. View

18.

Ke M, Xue L, Feyes D, Azizuddin K, Baron E, McCormick T . Apoptosis mechanisms related to the increased sensitivity of Jurkat T-cells vs A431 epidermoid cells to photodynamic therapy with the phthalocyanine Pc 4. Photochem Photobiol. 2008; 84(2):407-14. DOI: 10.1111/j.1751-1097.2007.00278.x. View

19.

Oleinick N, Morris R, Belichenko I . The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2003; 1(1):1-21. DOI: 10.1039/b108586g. View

20.

ZACKHEIM H, Amin S, Kashani-Sabet M, McMillan A . Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol. 1999; 40(3):418-25. DOI: 10.1016/s0190-9622(99)70491-3. View